MetaCap

Equillium (EQ) vs TuHURA Biosciences (HURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Equillium (EQ) has outperformed TuHURA Biosciences (HURA) over the past year, gaining 10.4% versus a loss of 28.2%. Over five years, EQ leads with a -80.4% price change compared with -99.9% for HURA. Equillium is the larger company by market cap ($87.3 million vs $82.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EQ+10.42%HURA-28.16%
+249%+79%-90%
Nov 21, 20251 yearNov 20, 2026
EQ-79.81%HURA-99.91%
+8%-48%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EQ versus HURA key metrics
MetricEQHURA
Share price$1.06$1.25
Market cap$87.26M$82.20M
1-day change-5.36%-8.09%
YTD return-31.61%+65.13%
1-year return+10.42%-28.16%
5-year return-80.41%-99.91%
EPS (TTM)$-0.12$-0.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-22.40M$-30.05M
52-week high$3.54$3.43
52-week low$0.81$0.41
Distance from 52-week high-70.06%-63.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+707.55%+543.20%
Average volume544.39K329.76K
Shares outstanding82.32M65.76M
Employees1422
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EQ has outperformed HURA by 38.6 percentage points over the past year.

About Equillium

EQ stock →

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About TuHURA Biosciences

HURA stock →

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

EQ vs HURA FAQ

Which is bigger, Equillium or TuHURA Biosciences?

Equillium (EQ) is larger, with a market capitalization of $87.26M compared with $82.20M for TuHURA Biosciences (HURA).

Which stock has performed better over the past year, EQ or HURA?

EQ returned +10.42% over the past 12 months, compared with -28.16% for HURA (price return, excluding dividends). Past performance does not predict future results.

Are Equillium and TuHURA Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons